[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
2019 Bio Top5 인터뷰
스폰서배너광고 안내  배너1
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
이정규 (Jung-Kyu Lee) 저자 이메일 보기
서울대학교 보라매병원
조회 569  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial
열기 Authors and Affiliations


Linezolid improves the treatment outcomes of multidrug-resistant tuberculosis substantially. We investigated whether use of linezolid instead of ethambutol increases the proportion of sputum culture conversion at 8 weeks of treatment in patients with pulmonary tuberculosis.

We did a phase 2, multicentre, randomised, open-label trial for patients with pulmonary tuberculosis at the three affiliated hospitals to Seoul National University and National Medical Center (Seoul-Seongnam, South Korea). Patients, aged 20-80 years, with a positive sputum for pulmonary tuberculosis, but without resistance to rifampicin, and current treatment administered for 7 days or fewer, were randomly assigned at a 1:1:1 ratio into three groups. The control group received ethambutol (2 months) with isoniazid, rifampicin, and pyrazinamide. The second group used linezolid (600 mg/day) for 2 weeks and the third group for 4 weeks instead of ethambutol for 2 months. We used a minimisation method to randomise, and stratified according to institution, cavitation on chest radiographs, and diabetes. The primary endpoint was the proportion of patients with negative culture conversion of sputum in liquid media after 8 weeks of treatment. The results of this trial were analysed primarily in the modified intention-to-treat population. The trial is registered with ClinicalTrials.gov, number NCT01994460.

Between Feb 19, 2014, and Jan 13, 2017, a total of 429 patients were enrolled and 428 were randomly assigned into either the control group (142 patients), the linezolid 2 weeks group (143 patients), or the linezolid 4 weeks group (143 patients). Among them, 401 were eligible for primary efficacy analyses. In the modified intention-to-treat analyses, negative cultures in liquid media at 8 weeks of treatment were observed in 103 (76·9%) of 134 control patients, 111 (82·2%) of 135 in the linezolid 2 weeks group, and 100 (75·8%) of 132 in the linezolid 4 weeks groups. The difference from the control group was 5.4% (95% CI −4·3 to 15·0, p=0·28) for the linezolid 2 weeks group and −1·1% (−11·3 to 9·1, p=0·83) for the linezolid 4 weeks group. Numbers of patients who experienced at least one adverse event were similar across the groups (86 [62·8%] of 137 in control, 79 [57·2%] of 138 in the linezolid 2 weeks group, and 75 [62·0%] of 121 in the linezolid 4 weeks group). Resistance to linezolid was not identified in any patient.

Higher rates of culture conversion at 8 weeks of treatment with short-term use of linezolid were not observed. However, safety analyses and the resistance profile suggested the potential role of linezolid in shortening of treatment for drug-susceptible tuberculosis.

Ministry of Health and Welfare, South Korea.

- 형식: Research article
- 게재일: 2018년 11월 (BRIC 등록일 2018-12-05)
- 연구진: 국내연구진태극기
- 분야: Medicine
경제적 의사결정의 개별과정을 동질한 성격의 뉴런으로 구현하기[Neuron]
발표: 유승범 (University of Minnesota)
일자: 2020년 1월 29일 (수) 오전 10시 (한국시간)
언어: 영어
참석자 접수신청하기
유전자 편집 기술을 활용한 도시농업 적합 작물 개발[Nat. Biotechnol.]
발표: 권춘탁 (Cold Spring Harbor Labor...)
일자: 2020년 2월 19일 (수) 오전 11시 (한국시간)
언어: 한국어
참석자 접수신청하기

  댓글 0
이정규 님 전체논문보기 >
이지연 (국립중앙의료원)
임재준 (서울대학교 의과대학)
관련분야 논문보기

Google (by Jung-Kyu Lee)
Pubmed (by Jung-Kyu Lee)
프리미엄 Bio일정 Bio일정 프리미엄 안내
[BRIC Webinar]경제적 의사결정의 개별과정을 동질한 성격의 뉴런으로 구현하기[Neuron]
[BRIC Webinar]Overview of NGS library Preparation[필코리아테크놀로지]
[BRIC Webinar]Overview of NGS library Preparation[필코리아테크놀로지]
사전접수: ~2020.01.21
날짜: 2020.01.22
Online 개최
[무료/ 취업연계]바이오QC 실무과정 8기 모집
[무료/ 취업연계]바이오QC 실무과정 8기 모집
사전접수: ~2020.02.10
날짜: 2020.03.02~06.12
장소: 성남시 분당구 황새울로
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS